Home - Yuhan USA
Yuhan's Global Network Yuhan USA is actively searching for business development and strategic partnership opportunities
About - Yuhan USA
Yuhan USA is a global business development arm of Yuhan Corporation. We are exploring collaborative opportunities and seeking partnerships with global academic research centers, biotech startups, and …
Yuhan Secures USD 45 Million Milestone Payment for Lecraza’s Entry …
Nov 6, 2025 · Yuhan Corporation announced that it will receive a milestone payment of USD 45 million (approximately KRW 69 billion) from Janssen Biotech following the commercial launch of Lazertinib …
Yuhan Presents Phase 1b Part 2 Results for Lesigercept - Shows Efficacy ...
Jun 25, 2025 · Yuhan Corporation presented positive Phase 1b Part 2 results for its investigational anti-IgE biologic Lesigercept (YH35324) at the EAACI 2025 Annual Meeting in Glasgow.
Yuhan’s HER2×4-1BB Bispecific Antibody YH32367 Shows Early Efficacy …
May 9, 2025 · At the AACR 2025 Annual Meeting, Yuhan Corporation presented encouraging interim results from a Phase 1 trial of YH32367, a bispecific antibody targeting HER2 and 4-1BB, in patients …
Yuhan Corporation Announces Free Supply of Its New Lung Cancer …
Jul 12, 2023 · Yuhan Corporation, a leading pharmaceutical company, has announced that it will provide its newly developed drug, “Lazertinib,” as a first-line treatment for free until it is covered by health …
Yuhan Corporation acquires Progen, a multi-target antibody company ...
Apr 6, 2023 · Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc., a company with multi-target …
Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in …
Nov 8, 2021 · Yuhan Corporation is spurring overseas open innovation expansion and strengthening its global position by continuously investing in ‘Yuhan USA’, a leading edge for global advancement.
Yuhan Corporation to recoup KRW 200 billion investment in five years
Jul 30, 2020 · Yuhan, which formerly led the Korean pharmaceutical industry with its sales force, has transformed itself into an innovative drug developer through investment in its R&D program and in & …
Janssen Gains China Approval for Lazertinib - yuhan-usa.com
Aug 4, 2025 · Yuhan Corporation’s novel EGFR-targeting non-small cell lung cancer (NSCLC) therapy Leclaza (lazertinib) has received official marketing approval in China, further solidifying its global …